Thai H. Ho, MD, PhD, discusses the role of TKI monotherapy in the first-line treatment of patients with metastatic renal cell carcinoma.
Thai H. Ho, MD, PhD
Advertisement
Articles by Thai H. Ho, MD, PhD
Thai H. Ho, MD, PhD, discusses frontline treatment regimens in metastatic renal cell carcinoma.
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.
Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses common molecular subtype and phenotype alterations in the epigenetic pathway that are used to predict response to treatment.
Advertisement
Latest Updated Articles
Dr. Ho on How Molecular Subtypes Affect SequencingMarch 2nd 2018
Dr. Ho on Managing Immune-Related AEs in Kidney CancerSeptember 11th 2018
Dr. Ho on Frontline Treatment Regimens in mRCCNovember 4th 2019
Dr. Ho on First-Line TKI Monotherapy in mRCCNovember 12th 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5